Physician profile
Ayham Shneker
NPI 1871557454
$11,960.84
in general payments reported to CMS, 2019-2025
63 companies · $826 in 2025
The $826 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,762 · 2020: $1,658 · 2021: $2,398 · 2022: $1,740 · 2023: $1,368 · 2024: $1,209 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,402.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,682.55 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Novo Nordisk As | $1,097.79 | 2019 | |
| Lilly USA, LLC | $960.26 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $878.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $746.07 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $429.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $424.93 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $415.45 | 2019-2025 | Arexvy, Shingrix |
| Allergan, INC. | $404.55 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $369.34 | 2021-2025 | |
| Corcept Therapeutics | $355.43 | 2020-2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.41 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $282.91 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $274.28 | 2019-2023 | Belsomra |
| Esperion Therapeutics, INC. | $251.08 | 2020-2024 | Nexletol |
Show all 61 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayham Shneker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.